Epigral Limited

BSE: 543332 NSE: MFL
Epigral Limited - chemicals and materials in Ahmadabad City, Gujarat, India. FY 2026 financials & compliance.
CIN L24100GJ2007PLC051717 Incorporated 11 September 2007 ROC Ahmedabad HQ Ahmadabad City, Gujarat, India
Active Listed - NSE: MFL · BSE: 543332 Public Limited Company chemicals and materials
Data last updated
Market Cap
₹4,620 Cr
EPIGRAL · NSE
Share Price
₹1,060.60
-0.97% today
Revenue
₹2,527 Cr
FY 2025-26 · +6.6% YoY
EBITDA
₹566 Cr
Margin 22.4%
Net Profit
₹330 Cr
FY 2025-26 · -7.5% YoY
P/E (TTM)
17.4x
P/B 2.1x
ROE
16.1%
ROCE 15.5%
Debt / Equity
0.28
Interest cover 18.1x

About Epigral Limited

Data last updated: 26 September 2026

Epigral Limited is a public limited company based in Ahmadabad City, Gujarat, India. It specialises in industrial chemicals, a part of the broader chemicals and materials sector. Incorporated on 11 September 2007, the company has been in operation for over 19 years.

Registered with ROC Ahmedabad under CIN L24100GJ2007PLC051717. Listed on BSE: 543332 and NSE: MFL.

Capital: an authorised share capital of ₹573.13 Cr and a paid-up capital of ₹43.14 Cr. It is led by directors including Karana Rameshbhai Patel and Priyanka Vishal Chopra.

Last AGM: 08 June 2026. Financial statements filed for year ended 31 March 2026. Office: Ahmadabad City, Gujarat.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹2,527.18 Cr, a decline of 0.9% compared to the previous year. The net worth stands at ₹2,221.43 Cr (up 16.64% YoY). Total assets are valued at ₹2,812.92 Cr (up 12.36% YoY).

The company has a workforce of approximately 967 employees as per the latest available data.

The company is associated with 1 brand - Epigral. As per MCA filings, the company has open charges of ₹1,584.75 Cr and satisfied charges of ₹2,310.5 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website meghmanifinechem.com.

Company Details of Epigral Limited
CIN L24100GJ2007PLC051717
Registration Number 051717
Incorporation Date 11 September 2007
ROC Ahmedabad
Listing Status Listed (BSE: 543332, NSE: MFL)
Company Status Active
Date of Last AGM 08 June 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
Key People
Maulik Jayantibhai Patel Managing Director Kaushal Ashishbhai Soparkar Whole-Time Director Sanjay Surendra Jain Cfo
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    meghmanifinechem.com
  • Social Media
  • Registered Address
    Epigral Tower 5Th 6Th & 7Th Floor, B/H Safal Profitaire Corporate Road Prahladnagar, Ahmadabad City, Gujarat, India – 380015
  • Industry
    Chemicals and Materials, Industrial Chemicals
Company report
Epigral Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Epigral Limited report

Financials, compliance, directors, charges, ownership and filings for Epigral Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Epigral Limited

Epigral Limited has one previous CIN (Corporate Identification Number): U24100GJ2007PLC051717. The current CIN is L24100GJ2007PLC051717, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24100GJ2007PLC051717 Current
U24100GJ2007PLC051717 Previous

Associated Brands with Epigral Limited

Epigral Limited operates one associated brand: Epigral. These brands represent Epigral Limited's diversified market presence and brand portfolio.

Brand Description Website
Epigral
Essential derivatives and specialty chemicals are manufactured for various industries. epigral.com

Business Activity of Epigral Limited

Epigral Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Epigral Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Epigral Limited

Epigral Limited is audited by S R B C & CO LLP for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
S R B C & CO LLP Locked Locked Locked
Premium access

Complete auditor history for Epigral Limited

Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors and KMP of Epigral Limited

Epigral Limited currently reports 12 directors and 2 key managerial personnel. 9 former directors have served the organization.

Current Directors and KMP
Name Designation Appointment Date Tenure Status
Karana Rameshbhai Patel
Also directs: Navratan Specialty Chemicals Llp, Uniworth Enterprises Llp, Meghmani Dyes And Intermediates Llp and 5 more
Director 10 May 2016 10 Years 4 Months Current
Priyanka Vishal Chopra
Also directs: Sprinter Ventures Llp, Harsha Engineers International Limited, Prava Innovate Private Limited
Director 28 Feb 2025 1 Years 6 Months Current
Gaurang Ghanshyam Trivedi Company Secretary 23 Apr 2024 2 Years 5 Months Current
Nirali Bhavinbhai Parikh Director 30 Mar 2015 11 Years 5 Months Current
Maulik Jayantibhai Patel
Also directs: Meghmani Organics Limited, Meghmani Crop Nutrition Limited, Kilburn Chemicals Limited and 4 more
Managing Director 10 May 2016 10 Years 4 Months Current
Raju Swamy Director 20 May 2021 5 Years 4 Months Current
Showing 6 of 14 current directors and KMP. View all directors and KMP

Financials of Epigral Limited FY 2025-26 filings available

Epigral Limited reported revenue of ₹2,527.18 Cr (down 0.9% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹2,527 Cr
-0.9% YoY
EBITDA
₹566 Cr
-20.4% YoY
Profit After Tax
₹330 Cr
-7.5% YoY
Net Worth
₹2,221 Cr
+16.6% YoY
Total Assets
₹2,813 Cr
+12.4% YoY
Total Debt
₹572 Cr
-3.5% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue2,5272,5501,9292,1881,551829
Revenue growth+6.6%+27.0%-3.4%+44.0%+83.6%+9997.0%
EBITDA566711481689509261
EBITDA margin+22.4%+27.9%+24.9%+31.5%+32.9%+31.5%
Profit before tax341541291522383161
Net profit330356195353253101
Net profit margin+13.0%+14.0%+10.1%+16.1%+16.3%+12.2%
EPS (₹)76.9582.9147.1485.0360.8424.27
Balance sheet
Total assets2,8132,5032,2231,9511,7221,228
Net worth2,2211,9051,3091,179937684
Total debt572593909769782542
Cash & bank5.4622.196.7915.1125.090.68
Net working capital352343139105137(8.78)
Cash flow
Cash from operations436441398626284229
Cash from investing(355)(262)(401)(437)(455)(197)
Cash from financing(94.48)(164)(7.60)(200)195(31.90)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue705736597587607628645626
Revenue growth (YoY)+16.3%+17.3%-7.5%-6.2%-6.9%+19.6%+36.8%+30.9%
Other income4.66(0.57)5.561.748.533.673.956.32
EBITDA179168103132163173183178
EBITDA margin+25.4%+22.8%+17.2%+22.5%+26.9%+27.6%+28.3%+28.5%
Depreciation42.9041.6942.7542.3141.5433.9532.9132.25
Interest7.2215.8010.9521.8423.3711.77(0.07)27.32
Profit before tax13411054.5669.65107131154125
Tax34.0028.5915.4518.43(53.68)44.4449.9943.88
Net profit99.7480.9539.1151.2216186.8910481.30
EPS (₹)23.1218.769.0711.8737.2520.1424.2519.57
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,5272,5501,9292,1881,551829611
Revenue growth+6.6%+27.0%-3.4%+44.0%+83.6%+36.2%+4.4%
EBITDA567711481689509261194
EBITDA margin+22.4%+27.9%+24.9%+31.5%+32.9%+31.5%+31.8%
Profit before tax342540291523383161141
Net profit326352196353253101112
Net profit margin+12.9%+13.8%+10.2%+16.2%+16.3%+12.2%+18.3%
EPS (₹)77.1982.6847.1285.0460.8424.2726.95
Balance sheet
Total assets2,8132,5022,2231,9511,7221,2281,117
Net worth2,2211,9041,3091,179937684583
Total debt572593909769782542526
Cash & bank5.4622.196.7915.0625.040.680.10
Net working capital352343139105137(8.83)(24.82)
Cash flow
Cash from operations436441398626284229165
Cash from investing(355)(262)(401)(437)(455)(197)(363)
Cash from financing(94.48)(164)(7.60)(200)195(31.90)69.41
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue705736597587607628645626
Revenue growth (YoY)+16.3%+17.3%-7.5%-6.2%-6.9%+19.6%+36.8%+30.9%
Other income4.10(0.57)5.561.748.253.403.865.55
Total expenses526568494455443454463448
EBITDA179169103132163173183178
EBITDA margin+25.4%+22.9%+17.2%+22.5%+26.9%+27.6%+28.3%+28.5%
Depreciation42.9041.6942.7542.3141.5433.9532.9132.25
Interest7.2215.8010.9521.8423.3711.77(0.07)27.32
Profit before tax13311154.6069.95107131154124
Tax34.0028.5915.4518.43(53.68)44.4449.9943.88

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 26 Sep 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue705736597587607628645626
Revenue growth (YoY)+16.3%+17.3%-7.5%-6.2%-6.9%+19.6%+36.8%+30.9%
Other income4.66(0.57)5.561.748.533.673.956.32
EBITDA179168103132163173183178
EBITDA margin+25.4%+22.8%+17.2%+22.5%+26.9%+27.6%+28.3%+28.5%
Depreciation42.9041.6942.7542.3141.5433.9532.9132.25
Interest7.2215.8010.9521.8423.3711.77(0.07)27.32
Profit before tax13411054.5669.65107131154125
Tax34.0028.5915.4518.43(53.68)44.4449.9943.88
Net profit99.7480.9539.1151.2216186.8910481.30
EPS (₹)23.1218.769.0711.8737.2520.1424.2519.57
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue2,5272,5501,9292,1881,551829
Revenue growth+6.6%+27.0%-3.4%+44.0%+83.6%+9997.0%
Other income14.9816.206.607.984.112.19
Total expenses1,9611,8391,4481,4991,041567
Employee cost11697.8181.3168.8551.9941.26
EBITDA566711481689509261
EBITDA margin+22.4%+27.9%+24.9%+31.5%+32.9%+31.5%
Depreciation16813312410985.9173.54
Interest71.9653.2773.4965.5044.2729.11
Profit before tax341541291522383161
Tax8.7918394.8816913160.02
Net profit330356195353253101
Net profit margin+13.0%+14.0%+10.1%+16.1%+16.3%+12.2%
EPS (₹)76.9582.9147.1485.0360.8424.27
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital43.1443.1496.55152252252
Reserves & surplus2,1781,8611,2131,028684432
Shareholders' funds (net worth)2,2211,9051,3091,179937684
Minority interest0.000.000.000.000.000.00
Secured loans563585908766778538
Unsecured loans9.057.951.352.623.763.76
Total debt572593909769782542
Total liabilities2,8132,5032,2231,9511,7221,228
Assets
Gross block2,9742,9672,4062,3201,4751,424
Net block2,1172,2381,7671,8041,0681,102
Capital work in progress45163.89483158589126
Investments22.7698.1420.5820.550.000.00
Inventories34938826321215453.96
Sundry debtors417232179166256119
Cash & bank balances5.4622.196.7915.1125.090.68
Loans & advances56.0756.1453.4026.2411.407.81
Total current assets827699502420447181
Total current liabilities475355363315310190
Net working capital352343139105137(8.78)
Total assets2,8132,5032,2231,9511,7221,228
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash18.643.1814.2425.090.680.10
Net cash from operating activities436441398626284229
Net cash from investing activities(355)(262)(401)(437)(455)(197)
Net cash from financing activities(94.48)(164)(7.60)(200)195(31.90)
Net change in cash(13.62)15.46(11.06)(10.85)24.410.58
Closing cash5.4622.196.7915.1125.090.68
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth-0.9%+32.2%-11.8%+41.1%+87.2%+9997.0%
EBITDA growth-20.4%+47.7%-30.2%+35.2%+95.0%+9997.0%
PBT growth-37.0%+86.1%-44.4%+36.3%+138.4%+9997.0%
Net income growth-7.5%+82.5%-44.7%+39.8%+150.7%+9997.0%
Revenue CAGR (3Y)+4.9%+18.0%+32.5%---
EBITDA CAGR (3Y)-6.3%+11.7%+22.6%---
Profitability & leverage
Net income margin+13.1%+14.0%+10.2%+16.1%+16.3%+12.2%
Return on capital employed+15.5%+25.2%+17.5%+32.0%+29.0%+15.5%
Return on net worth+16.1%+22.7%+16.9%+39.4%+42.2%+21.3%
Debt / equity0.280.470.670.730.820.79
Long-term debt / equity0.190.290.370.470.560.50
Interest cover18.099.2120.5511.2910.4515.50
Efficiency & per share
Fixed asset turnover0.850.950.821.151.070.58
Inventory turnover6.867.838.1311.9614.9115.36
Debtors turnover7.7912.4111.1810.368.276.97
EPS (₹)76.9582.9147.1485.0360.8424.27
Dividend per share (₹)5.006.005.005.000.000.00
Book value per share (₹)514.94441.48301.83257.30174.72113.88
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue705736597587607628645626
Revenue growth (YoY)+16.3%+17.3%-7.5%-6.2%-6.9%+19.6%+36.8%+30.9%
Other income4.10(0.57)5.561.748.253.403.865.55
Total expenses526568494455443454463448
EBITDA179169103132163173183178
EBITDA margin+25.4%+22.9%+17.2%+22.5%+26.9%+27.6%+28.3%+28.5%
Depreciation42.9041.6942.7542.3141.5433.9532.9132.25
Interest7.2215.8010.9521.8423.3711.77(0.07)27.32
Profit before tax13311154.6069.95107131154124
Tax34.0028.5915.4518.43(53.68)44.4449.9943.88
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,5272,5501,9292,1881,551829611
Revenue growth+6.6%+27.0%-3.4%+44.0%+83.6%+36.2%+4.4%
Other income14.9815.216.527.984.112.192.31
Total expenses1,9601,8391,4481,4991,041567416
Employee cost11697.8181.3168.8551.9941.2632.72
EBITDA567711481689509261194
EBITDA margin+22.4%+27.9%+24.9%+31.5%+32.9%+31.5%+31.8%
Depreciation16813312410985.9173.5444.30
Interest71.9653.2773.4965.5044.2729.1111.14
Profit before tax342540291523383161141
Tax8.7918394.8816913160.0228.99
Net profit326352196353253101112
Net profit margin+12.9%+13.8%+10.2%+16.2%+16.3%+12.2%+18.3%
EPS (₹)77.1982.6847.1285.0460.8424.2726.95
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital43.1443.1496.55152252252252
Reserves & surplus2,1781,8601,2131,028684432331
Shareholders' funds (net worth)2,2211,9041,3091,179937684583
Secured loans563585908766778538526
Unsecured loans9.057.951.352.623.763.760.00
Total debt572593909769782542526
Total liabilities2,8132,5022,2231,9511,7221,2281,117
Assets
Gross block2,9742,9672,4062,3201,4751,424688
Net block2,1172,2381,7671,8041,0681,102440
Capital work in progress45163.89483158589126691
Investments22.8097.1420.5720.620.050.050.00
Inventories34938826321215453.9648.40
Sundry debtors41723217916625611976.45
Cash & bank balances5.4622.196.7915.0625.040.680.10
Loans & advances56.0756.1453.4026.2411.407.817.13
Total current assets827699502419447181132
Total current liabilities475355363315310190157
Net working capital352343139105137(8.83)(24.82)
Total assets2,8132,5022,2231,9511,7221,2281,117
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash18.643.1814.1925.040.680.10129
Net cash from operating activities436441398626284229165
Net cash from investing activities(355)(262)(401)(437)(455)(197)(363)
Net cash from financing activities(94.48)(164)(7.60)(200)195(31.90)69.41
Net change in cash(13.62)15.46(11.01)(10.85)24.360.58(129)
Closing cash5.4622.196.7915.0625.040.680.10
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-0.9%+32.2%-11.8%+41.1%+87.2%+35.7%-14.1%
EBITDA growth-20.2%+47.7%-30.2%+35.2%+95.0%+34.6%-37.7%
PBT growth-36.7%+85.8%-44.4%+36.3%+138.4%+14.1%-41.8%
Net income growth-7.4%+79.8%-44.6%+39.8%+150.7%-9.8%-37.3%
Revenue CAGR (3Y)+4.9%+18.0%+32.5%+53.0%+29.7%+11.5%+15.9%
EBITDA CAGR (3Y)-6.3%+11.7%+22.6%+52.5%+17.8%+0.8%+10.5%
Profitability & leverage
Net income margin+13.2%+14.0%+10.2%+16.2%+16.3%+12.2%+18.4%
Return on capital employed+15.6%+25.1%+17.5%+32.0%+29.0%+16.2%+15.2%
Return on net worth+16.2%+22.6%+16.9%+39.4%+42.2%+23.9%+34.2%
Debt / equity0.280.470.670.730.810.840.85
Long-term debt / equity0.190.290.370.470.560.600.73
Interest cover18.059.2120.5511.2910.4515.507.44
Efficiency & per share
Fixed asset turnover0.850.950.821.151.070.781.03
Inventory turnover6.867.838.1311.9614.9116.1913.71
Debtors turnover7.7912.4111.1810.368.278.497.94
EPS (₹)77.1982.6847.1285.0460.8424.2726.95
Dividend per share (₹)5.006.005.005.000.000.000.00
Book value per share (₹)514.94441.24301.83257.32174.72113.8889.66
Want more history and ratios?
You're viewing the latest exchange-filed financials for Epigral Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Epigral Limited

As per the shareholding pattern for the quarter ended Jun 2026, promoters hold 68.80%, foreign institutional investors hold 1.00%, domestic institutional investors hold 5.60%, retail and other public shareholders hold 24.60% of Epigral Limited.

Promoters: 68.80%DII (Domestic Institutional): 5.60%FII (Foreign Institutional): 1.00%Retail & Others: 24.60%
Jun 2026
QUARTER
68.80% Promoters
5.60% DII (Domestic Institutional)
1.00% FII (Foreign Institutional)
24.60% Retail & Others
Promoter holding - history
Now 68.80% · Jun 2026High 68.80% · Sep 2025Low 68.80% · Sep 2025
67%67.8%68.5%69.3%70%Sep 2025Dec 2025Mar 2026Jun 2026Sep 2025: 68.80%Dec 2025: 68.80%Mar 2026: 68.80%Jun 2026: 68.80%68.80%68.80%
Shareholding trend - last 6 quarters
Jun 2026Mar 2026Dec 2025Sep 2025
Promoters68.80%68.80%68.80%68.80%
Public31.20%31.20%31.20%31.20%

Group Structure of Epigral Limited

Epigral Limited has 1 associated company. This group structure data is as of FY 2024. The corporate group structure reflects Epigral Limited's business expansion strategy and organizational complexity.

1
Associated companies

Charges & Borrowings of Epigral Limited

Open charges
₹1,584.75 Cr
Satisfied charges
₹2,310.5 Cr
Breakdown by lending institutions
Axis Bank Limited₹700.00 Cr
Others₹600.00 Cr
Hdfc Bank Limited₹284.75 Cr
Latest charge details
DateLenderAmountStatus
12 Jun 2024 Axis Bank Limited ₹350 Cr Open
22 Apr 2024 Axis Bank Limited ₹350 Cr Open
18 Jun 2021 Hdfc Bank Limited ₹284.75 Cr Open
17 Jun 2013 Others ₹600 Cr Open
20 Feb 2021 State Bank of India ₹190 Cr Satisfied

Total charge records: 20 View all charges

Employees and EPFO Compliance at Epigral Limited

Epigral Limited has a workforce of 967 employees as of Dec 03, 2024.

Employee count
967
Active EPFO establishments
1
Employee growth
4.88%
Premium access

Employee and EPFO history for Epigral Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Epigral Limited

Premium access

GST registrations and filing compliance for Epigral Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Epigral Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Epigral Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Epigral Limited

Premium access

MSME payment history for Epigral Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Epigral Limited

Premium access

Corporate group structure for Epigral Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Epigral Limited

Premium access

MCA filings and documents for Epigral Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Epigral Limited

Activity
08 Jun 2026
Epigral Limited last Annual general meeting of members was held on 08 Jun 2026 as per latest MCA records.
Activity
31 Mar 2026
Epigral Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Directors
15 Nov 2025
Rakesh Shyamlalji Agrawal was appointed as a Cfo on 15 Nov 2025 & has been associated with this company since 10 months 11 days.
Directors
28 Feb 2025
Priyanka Vishal Chopra was appointed as a Director on 28 Feb 2025 & has been associated with this company since 1 year 6 months.
Charges
29 Jan 2025
A charge registered on 30 May 2019 via Charge ID 100268462 with Hdfc Bank Limited was fully satisfied on 29 Jan 2025.
Charges
02 Jan 2025
A charge registered on 20 Feb 2021 via Charge ID 100422630 with State Bank Of India was fully satisfied on 02 Jan 2025.

Recent News on Epigral Limited

Frequently Asked Questions about Epigral Limited

Epigral Limited is an active public limited company in the chemicals and materials sector based in Ahmadabad City, Gujarat, India. It was incorporated on 11 September 2007 (19+ years old) and is registered under CIN L24100GJ2007PLC051717. Listed on BSE: 543332 and NSE: MFL. The company has 967 employees.

Epigral Limited reported revenue of ₹2,527.18 Cr for FY 2025-26 (down 0.9% YoY) based on consolidated financials.

The current directors and KMP of Epigral Limited are:

The primary industry of Epigral Limited is chemicals and materials. The company specifically operates in industrial chemicals. The company is currently active in this sector.

Yes. Epigral Limited is listed on both BSE (code: 543332) and NSE (symbol: MFL).

Epigral Limited can be reached at the registered office: Epigral Tower 5Th 6Th & 7Th Floor, BH Safal Profitaire Corporate Road Prahladnagar, Ahmadabad City, Gujarat, India – 380015, or through the website meghmanifinechem.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available